Localization of cytochrome P4502E1 enzyme in normal and cancerous gastric mucosa and association with its genetic polymorphism in unoperated and remnant stomach

Journal of Nippon Medical School

Volumn 78, Issue 4, 2011, Pages 224-234

  Kato, Shunji ^a   Naito, Zenya ^a   Matsuda, Noriko ^a   Onodera, Hiroyuki ^a   Sakurazawa, Nobuyuki ^a   Yamashita, Naoyuki ^a   Kanazawa, Yoshikazu ^a   Fujita, Itsuo ^a   Makino, Hiroshi ^a   Uchida, Eiji ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2E1; POLYCLONAL ANTIBODY; RESTRICTION ENDONUCLEASE;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA FLANKING REGION; ENDOCRINE CELL; ENZYME ACTIVITY; ENZYME LOCALIZATION; EPITHELIUM; FEMALE; GASTRECTOMY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HELICOBACTER INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; STAINING; STOMACH CANCER; STOMACH MUCOSA; STOMACH PH; WESTERN BLOTTING;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2E1; FEMALE; GASTRECTOMY; GASTRIC MUCOSA; GASTRIC STUMP; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEIN TRANSPORT; RISK FACTORS; STOMACH NEOPLASMS;

EID: 79961191168     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.78.224     Document Type: Article

References (37)

1. Shields PG, Harris CC: Molecular epidemiology and the genetics of environmental cancer. JAMA 1991; 266: 681-687.
2. International Agency for Research in Cancer: In World Cancer Report (Stewart BW, ed), 2003; pp 195-197, IARC Press, Lyon.
3. Kuroishi T, Hirose K, Tajima K, Tominaga S: Cancer Mortality in Japan (1950-1990). In Cancer Mortality and Morbidity Statistics: Japan and the World-1994, Gann Monograph on Cancer Research No. 41, 1994; pp 1-105, Japan Scientific Societies Press, Tokyo.
4. Kuroishi T, Hayakawa N, Kurihara M, Aoki K: Cancer Mortality in 33 Countries of the World (1953-1987). In Cancer Mortality and Morbidity Statistics: Japan and the World-1994, Gann Monograph on Cancer Research No. 41, 1994; pp 167-230, Japan Scientific Societies Press, Tokyo.
5. Correa P: Human Gastric carcinogenesis: A multistep and multifactorial process- First American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1991; 52: 6735-6740.
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori. In IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 61, 1994; pp 177-240, International Agency for Research on Cancer, Lyon France.
7. Kato S, Matsukura N, Tsukada K, et al.: Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007; 98: 790-794.
8. Matsukura N, Tajiri T, Kato S, et al.: Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy. Gastric Cancer 2003; 6: 100-107.
9. Yang CS, Yoo J, Ishizaki H, Hong JY: Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990; 22: 147-159.
10. Guengerich FP, Kim DH, Iwasaki M: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-179.
11. Lieber CS: Cytochrome P-450 2E1: Its physiological and pathological role. Physiological Review 1997; 77: 517-544.
12. Bartsch H, Montesano R: Relevance of nitrosamines to human cancer. Carcinogenesis 1984; 5: 1381-1393.
13. Okano T, Gemma A, Kudoh S: Serum Biomarker of Lung Carcinogenesis Induced by Cigarette Smoking. J Nippon Med Sch 2008; 75: 53-55.
14. Heim M, Meyer UA: Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
15. Hildesheim A, Anderson LM, Chen CJ, et al.: CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. Journal of the National Cancer Institute 1997; 89: 1207-1212.
16. Hayashi S, Watanabe J, Kawajiri K: Genetic polymorphisms in the 5́-flanking region change transcriptional regulation of the human cytochrome p4502E1 gene. J Biochem (Tokyo) 1991; 110: 559-565.
17. Kato S, Onda M, Matsukura N, et al.: Genetic polymorphisms of the cancer related gene and Helicobacter pylori infection in Japanese gastric cancer patients. An age and gender matched casecontrol study. Cancer 1996; 77: 1654-1661.
18. Nishimoto IN, Hanaoka T, Sugimura H, et al.: Cytochrome P450 polymorphism in gastric cancer in Brazil: Case-control studies of Japanese Brazilians and non-Japanese Brazilians, Cancer Epidemiology. Biomarkers & Prevention 2000; 9: 675-680.
19. Kato S, Tajiri T, Matsukura N, et al.: Genetic polymorphisms of aldehyde dehydrogenase 2, cytochrome p450 2E1 for liver cancer risk in HCV antibody-positive Japanese patients and the variations of CYP2E1 mRNA expression levels in the liver due to its polymorphism. Scand J Gastroenterol 2003; 38: 886-893.
20. Tsutsumi M, Wang JS, Takase S, Takada A: Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P 4502 E 1 genotypes. Alcohol & Alcoholism 1994; 29: 29-32.
21. Murray GI, Taylor MC, Burke MD, Melvin WT: Enhanced expression of cytochrome P450 in stomach cancer. British Journal of Cancer 1998; 77: 1040-1044.
22. Naylor G, Axon A: Role of bacterial overgrowth inthe stomach as an additional risk factor for gastritis. Can J Gastroenterol 2003; 17: 13B-17B.
23. Hirose Y, Naito Z, Kato S, Onda M, Sugisaki Y: Immunohistochemical study of CYP 2 E 1 in hepatocellular carcinoma carcinogenesis: examination with newly prepared anti-human CYP2E1 antibody. J Nippon Med Sch 2002; 69: 243-251.
24. Cole CB, Fuller R, Mallet AK, et al.: The influence of the host on expression of intestinal microbial enzyme activities involved in metabolism of foreign compounds. J Applied Bacteriol 1985; 59: 549-553.
25. Powell H, Kitteringham NR, Pirmohamed M, Smith DA, Park DK: Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. Pharmacogenetics 1998; 8: 411-421.
26. Hildesheim A, Chen CJ, Caporaso NE, et al.: Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan, Cancer Epidemiology. Biomarkers & Prevention 1995; 4:607-610.
27. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E: Genetic polymorphism of Nacetyltransferase-2, glutathione S-transferase-M 1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. Journal of Clinical Pathology 1998; 51: 294-298.
28. Lin DX, Tang YM, Peng Q, Lu SX, Ambrosone CB, Kadlubar FF: Susceptibility to esophageal cancer and genetic polymorphisms in glutathione Stransferases T1, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiology, Biomarkers & Prevention 1998; 7: 1013-1018.
29. Tan W, Song N, Wang GQ, et al.: Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China, Cancer Epidemiology. Biomarkers & Prevention 2000; 9: 511-556.
30. Miki K, Ichinose M, Ishikawa KB, et al.: Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res 1993; 84: 1086-1090.
31. Tomtitchong P, Onda M, Matsukura N, et al.: Helicobacter pylori infection in the remnant stomach after gastrectomy: With special reference to the difference between Billroth I and II anastomosis. J Clin Gastroenterol 1998; 27: 154-158.
32. Fox JG: The role of Helicobacter pylori species in newly recognized gastrointestinal tract diseases of animals. Lab Animal Science 1997; 47: 222-255.
33. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789.
34. Kaminishi M, Shimizu N, Yamaguchi H, Hashimoto M, Sakai S, Oohara T: Different carcinogenesis in the gastric remnant after gastrectomy for gastric cancer. Cancer 1996; 77: 1646-1653.
35. Fox JG, Dewhirst FE, Shen Z, et al.: Hepatic helicobacter species identified in bile and gallbladder tissues from chileans with chronic cholecystitis. Gasteroenterol 1998; 114: 755-763.
36. Kato S, Matsukura N, Matsuda N, Tsukada K, Naito Z, Tajiri T: Helicobacter pylori eradication therapy modulates acidity and interleukin-1beta mRNA levels in unoperated stomach and in remnant stomach after gastrectomy in gastric cancer patients. Aliment Pharmacol Ther Suppl 4 2006; 24: 278-284.
37. Kato S, Matsukura N, Matsuda N, Tsuchiya S, Naito Z, Tajiri T: Normalization of pH level and gastric mucosa after eradication of H. pylori in the remnant stomach. J Gastroenterol Hepatol 2008; 23: S258-S261.